Fig. 5: MiR-23b-3p and ANXA2 are the downstream targets of hsa_circ_0013561. | Cancer Gene Therapy

Fig. 5: MiR-23b-3p and ANXA2 are the downstream targets of hsa_circ_0013561.

From: Hsa_circ_0013561 promotes epithelial-mesenchymal transition and tumor progression by regulating ANXA2 via miR-23b-3p in ovarian cancer

Fig. 5

A AGO2 RNA-binding protein immunoprecipitation. All data are shown as the mean ± SD. ***P < 0.001 compared to IgG. B circRNA pull-down assay. 0013561 is referred to as hsa_circ_0013561. **P < 0.01 compared to negative control (NC) probe. C The luciferase activity of HEK293T cells with hsa_circ_0013561-Wt or hsa_circ_0013561-Mut co-transfected with different miRNA mimics or control (NC) mimics. D Prediction of miR-23b-3p binding sites in hsa_circ_0013561. The mutated (Mut) version of hsa_circ_0013561 was constructed. E Relative luciferase activity was tested in HEK293T cells with hsa_circ_0013561-Wt or hsa_circ_0013561-Mut co-transfected with miR-23b-3p mimics or NC mimics, ***P < 0.001. F Prediction of miR-23b-3p binding sites within the 3’ UTR of ANXA2. The Mut version of ANXA2 3’-UTR is shown. G Relative luciferase activity was tested in HEK293T cells with ANXA2 3’ UTR-Wt or ANXA2 3’ UTR-Mut co-transfected with miR-23b-3p mimics or NC mimics, ***P < 0.001. H Bioinformatics analysis (http://www.oncolnc.org/) showed the survival rate between OC patients with high and low ANXA2 expression.

Back to article page